<DOC>
	<DOC>NCT00726115</DOC>
	<brief_summary>The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects</brief_summary>
	<brief_title>Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criteria: Body mass index in the range of 18 to 30 kg/m2 and body weight greater than or equal to 50 kg. Body weight for elderly subjects must be greater than or equal to 45 kg. history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12lead ECG readings. Exclusion criteria: Presence or history of any disorder that may prevent the successful completion of the study. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal (GI), endocrine, immunologic, dermatologic, hematologic, neurologic or psychiatric disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>